Other headlines:FDA clears perfusion software
The newest release of a web-based insurance eligibility verification tool developed by MedCurrent includes capabilities for imaging centers to automate insurance workflow, eliminate errors, reduce denied claims, speed collections, and improve cash flow. MedCurrent Verify connects to databases from more than 350 U.S.-based insurance carriers to secure real-time patient coverage information. Extending this capability to imaging centers will help centers improve claim submission accuracy and optimize reimbursement, according to MedCurrent. This specially developed version of Verify includes specialty templates that deliver radiology-specific eligibility information first, eliminating the need for time-consuming scrolling.
Prism Clinical Imaging has been cleared by the FDA to begin marketing a suite of brain perfusion software programs designed to make functional MRI, diffusion tensor imaging, and advanced physiological studies available in general clinical practice. One module, called Prism Acquire, addresses contrast injection, including preload, and acquisition of time course data on popular MR scanners using gradient-echo and/or spin-echo sequences. The second, Prism Process, provides model-free automatic time course analysis with patented algorithms for leakage correction. The third, Prism View, displays the resulting cerebral blood volume maps integrated with other functional and physiological information and makes them available for export to PACS, treatment planning, and neuronavigation systems.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.